Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: five ways taxes could go up later this year, ...

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: we sample 13 decaf teas in Our Verdict - and ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

The yields on UK ten year bonds rose sharply on Wednesday as Keir Starmer failed to guarantee the job of chancellor Rachel ...

Compared to the aggregate P/E ratio of 27.38 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of ...